Brimonidine
- Generic Name
- Brimonidine
- Brand Names
- Alphagan, Combigan, Lumify, Mirvaso, Onreltea, Qoliana, Simbrinza
- Drug Type
- Small Molecule
- Chemical Formula
- C11H10BrN5
- CAS Number
- 59803-98-4
- Unique Ingredient Identifier
- E6GNX3HHTE
- Background
Brimonidine is an alpha-adrenergic agonist and 2-imidazoline derivative that was first introduced in 1996. It is considered to be a third generation alpha-2 aadrenergic receptor agonist, since it displays preferential binding at alpha-2 adrenoceptors over alpha-1 receptors. Brimonidine displays a higher selectivity toward the alpha-2 adrenergic receptors tha...
- Indication
Opthalmic
Indicated for lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension as monotherapy or combination product with brinzolamide.
Topical
Indicated for the treatment of persistent (non-transient) facial erythema of rosacea in adults 18 years of age or older.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Ocular Hypertension, Facial erythema
- Associated Therapies
- -
Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 12
- Registration Number
- NCT02039765
- Locations
- 🇺🇸
Bausch & Lomb, Incorporated, Rochester, New York, United States
Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants
- Conditions
- Interventions
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 507
- Registration Number
- NCT01959243
- Locations
- 🇺🇸
Bausch Site 3, Phoenix, Arizona, United States
🇺🇸Bausch Site 2, Philadelphia, Pennsylvania, United States
🇺🇸Bausch Site 1, Andover, Massachusetts, United States
Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness
- Conditions
- Interventions
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 60
- Registration Number
- NCT01959230
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Memphis, Tennessee, United States
Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy
- Conditions
- Interventions
- First Posted Date
- 2012-11-14
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- BCN Peptides
- Target Recruit Count
- 450
- Registration Number
- NCT01726075
- Locations
- 🇬🇧
Gloucestershire Hospitals NHS Foundation Trust (CHGH), Cheltenham, Gloucestershire, United Kingdom
🇮🇹Universita Vita-Salute San Raffaele (USR), Milano, Italy
🇪🇸Institut Catala de la Salut - Hospital Universitari Vall d'Hebron (ICS-HUVH), Barcelona, Spain
Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy
- Conditions
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2011-05-02
- Lead Sponsor
- Nanduri, Padma, M.D., FACS
- Target Recruit Count
- 22
- Registration Number
- NCT01345448
- Locations
- 🇺🇸
Eye Surgical and Medical Associates, Visalia, California, United States
Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature
- Conditions
- Interventions
- First Posted Date
- 2010-09-14
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 40
- Registration Number
- NCT01201551
- Locations
- 🇨🇭
University of Basel, Dept. of Ophthalmology, Basel, Switzerland
Aqueous Humor Dynamics and Brimonidine
- Conditions
- Interventions
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 35
- Registration Number
- NCT01144494
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab
- Conditions
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2008-12-09
- Lead Sponsor
- University of Sao Paulo
- Registration Number
- NCT00804921
- Locations
- 🇧🇷
School of Medicine - Clinical Hospital, Ribeirao Preto, SP, Brazil
Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)
- Conditions
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2008-12-04
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00698945
- Locations
- 🇺🇸
North Bay Eye Associates, Inc., Petaluma, California, United States
Brimonidine vs ALTP in Progressing Human Glaucoma
- Conditions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2007-04-27
- Lead Sponsor
- University of Parma
- Target Recruit Count
- 50
- Registration Number
- NCT00466479
- Locations
- 🇮🇹
sezione di Oftalmologia, Parma, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.